Tetsuya Nakatsura

List of Publications by Year
in descending order

98 papers	4,956 citations	109321 35 h-index	98798 67 g-index
99 all docs	99 docs citations	99 times ranked	5876 citing authors

#	Article	IF	Citations
1	Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. British Journal of Cancer, 2022, 126, 606-614.	6.4	12
2	Development of antigenâ€prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Science, 2022, , .	3.9	4
3	Component with abundant immuneâ€related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Cancer Science, 2022, , .	3.9	3
4	Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 2021, 44, 10-15.	2.6	14
5	Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations. Histopathology, 2021, 78, 987-999.	2.9	3
6	Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. Pathobiology, 2021, 88, 218-227.	3.8	2
7	Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. Genome Biology, 2021, 22, 9.	8.8	58
8	A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nature Communications, 2021, 12, 430.	12.8	111
9	Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma. Cancers, 2021, 13, 550.	3.7	6
10	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. Cancer Immunology Research, 2021, 9, 624-636.	3.4	13
11	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. International Journal of Cancer, 2021, 149, 546-560.	5.1	18
12	A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clinical Cancer Research, 2021, 27, 3714-3724.	7.0	61
13	Immune cell therapy against disseminated melanoma by utilizing induced pluripotent stem cell-derived myeloid cell lines producing interferon-beta or interleukin-15/interleukin-15 receptor alpha. Journal of Dermatological Science, 2021, 102, 133-136.	1.9	3
14	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. Journal of Immunology and Regenerative Medicine, 2021, 12, 100042.	0.4	0
15	Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. Molecular Therapy - Methods and Clinical Development, 2021, 21, 171-179.	4.1	11
16	Greater extent of bloodâ€tumor TCR repertoire overlap is associated with favorable clinical responses to PDâ€1 blockade. Cancer Science, 2021, 112, 2993-3004.	3.9	5
17	Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1035-1054.	3.7	17
18	Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer. Anticancer Research, 2021, 41, 4741-4751.	1.1	1

#	Article	IF	Citations
19	Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. Frontiers in Oncology, 2020, 10, 564714.	2.8	8
20	Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. OncoImmunology, 2020, 9, 1814620.	4.6	13
21	Nonâ€“clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cellâ€derived antiâ€“glypicanâ€3 chimeric antigen receptorâ€expressing natural killer/innate lymphoid cells. Cancer Science, 2020, 111, 1478-1490.	3.9	74
22	Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Science, 2020, 111, 23-35.	3.9	25
23	Plasma and tumoral glypicanâ€3 levels are correlated in patients with hepatitis C virusâ€related hepatocellular carcinoma. Cancer Science, 2020, 111, 334-342.	3.9	13
24	Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in nonâ€“small cell lung cancer. Cancer Science, 2020, 111, 2736-2746.	3.9	12
25	Peptide vaccine as an adjuvant therapy for glypicanâ€3â€positive hepatocellular carcinoma induces peptideâ€specific CTLs and improves long prognosis. Cancer Science, 2020, 111, 2747-2759.	3.9	19
26	Usefulness of plasma fullâ€‘length glypicanâ€‘3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncology Letters, 2020, 19, 2657-2666.	1.8	9
27	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. , 2019, 7, 195.		32
28	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Science, 2019, 110, 3049-3060.	3.9	20
29	Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. Cell Reports, 2019, 29, 162-175.e9.	6.4	26
30	Higher human lymphocyte antigen class I expression in earlyâ€stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. Cancer Science, 2019, 110, 1842-1852.	3.9	9
31	Next-Generation Cancer Immunotherapy Targeting Glypican-3. Frontiers in Oncology, 2019, 9, 248.	2.8	86
32	Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3. Biochemical and Biophysical Research Communications, 2019, 511, 711-717.	2.1	11
33	Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Scientific Reports, 2019, 9, 5925.	3.3	6
34	Efficacy of the NCCV Cocktailâ€1 vaccine for refractory pediatric solid tumors: A phase I clinical trial. Cancer Science, 2019, 110, 3650-3662.	3.9	8
35	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).. Journal of Clinical Oncology, 2019, 37, TPS179-TPS179.	1.6	2
36	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-analysis, 2019, 7, 80-95.	0.1	2

#	Article	IF	Citations
37	Cancer immunotherapyâ€targeted glypicanâ€3 or neoantigens. Cancer Science, 2018, 109, 531-541.	3.9	40
38	BCRâ€“ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cellular and Molecular Immunology, 2018, 15, 15-26.	10.5	5
39	Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. OncoImmunology, 2018, 7, e1377872.	4.6	39
40	Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell, 2018, 23, 850-858.e4.	11.1	110
41	Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Scientific Reports, 2018, 8, 13166.	3.3	46
42	Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. PLoS ONE, 2018, 13, e0191109.	2.5	100
43	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology, 2017, 6, e1346764.	4.6	69
44	Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget, 2017, 8, 37835-37844.	1.8	23
45	Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochemistry and Biophysics Reports, 2016, 5, 482-491.	1.3	11
46	Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. OncoImmunology, 2016, 5, e1238542.	4.6	37
47	Hepatocellular carcinoma cell sensitivity to Vî³9Vî2 T lymphocyte-mediated killing is increased by zoledronate. International Journal of Oncology, 2016, 48, 1794-1804.	3.3	13
48	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology, 2016, 5, e1129483.	4.6	125
49	Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochemical and Biophysical Research Communications, 2016, 469, 138-143.	2.1	23
50	Identification of glypican-3-derived long peptides activating both CD8⁺and CD4⁺T cells; prolonged overall survival in cancer patients with Th cell response. OncoImmunology, 2016, 5, e1062209.	4.6	36
51	A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516. PLoS ONE, 2016, 11, e0162394.	2.5	57
52	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2015, 46, 28-36.	3.3	69
53	Timeâ€lapse imaging assay using the BioStation CT : AÂsensitive drugâ€screening method for threeâ€dimensional cell culture. Cancer Science, 2015, 106, 757-765.	3.9	9
54	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. International Journal of Oncology, 2015, 46, 497-504.	3.3	29

#	Article	IF	Citations
55	Biomarkers for the early diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10573.	3.3	377
56	Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncology Reports, 2015, 33, 1837-1843.	2.6	621
57	Glypican 3 Expression in Pediatric Malignant Solid Tumors. European Journal of Pediatric Surgery, 2015, 25, 138-144.	1.3	28
58	Potentiality of immunotherapy against hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10314.	3.3	32
59	Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 35.	3.7	17
60	Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy. Human Vaccines and Immunotherapeutics, 2014, 10, 338-343.	3.3	27
61	Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncology Reports, 2014, 32, 33-39.	2.6	6
62	Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. Oncology Reports, 2014, 32, 1772-1778.	2.6	18
63	Large-scale expansion of Î³Î´ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. International Journal of Oncology, 2014, 45, 1847-1856.	3.3	8
64	Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncology Reports, 2014, 31, 1051-1058.	2.6	16
65	Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunology, Immunotherapy, 2013, 62, 639-652.	4.2	37
66	Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Human Pathology, 2013, 44, 526-533.	2.0	28
67	Peptide intra-tumor injection for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2013, 9, 1234-1236.	3.3	13
68	Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination. Human Vaccines and Immunotherapeutics, 2013, 9, 1228-1233.	3.3	30
69	Peptide vaccines for hepatocellular carcinoma. Human Vaccines and Immunotherapeutics, 2013, 9, 210-212.	3.3	28
70	Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide. International Journal of Oncology, 2013, 43, 1019-1026.	3.3	22
71	Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. International Journal of Oncology, 2013, 42, 831-838.	3.3	15
72	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2012, 40, 63-70.	3.3	54

#	Article	IF	Citations
73	Phase I Trial of a Glypican-3â€“Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical Cancer Research, 2012, 18, 3686-3696.	7.0	246
74	A glypican-3-derived peptide vaccine against hepatocellular carcinoma. OncoImmunology, 2012, 1, 1448-1450.	4.6	22
75	HLAâ€A2â€restricted glypicanâ€3 peptideâ€specific CTL clones induced by peptide vaccine show high avidity and antigenâ€specific killing activity against tumor cells. Cancer Science, 2011, 102, 918-925.	3.9	66
76	Glypicanâ€3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Science, 2011, 102, 1622-1629.	3.9	22
77	Postoperative serum Î±-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncology Reports, 2010, 24, 521-8.	2.6	42
78	Identification of Î²2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. Oncology Reports, 2010, 23, 1325-30.	2.6	13
79	The forkhead box M1 transcription factor as a candidate of target for antiâ€cancer immunotherapy. International Journal of Cancer, 2010, 126, 2153-2163.	5.1	29
80	Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G₁ arrest induction. Cancer Science, 2010, 101, 913-919.	3.9	19
81	Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. International Journal of Oncology, 2009, 34, 649-56.	3.3	58
82	Identification of the H2â€K^dâ€restricted cytotoxic T lymphocyte epitopes of a tumorâ€associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Science, 2009, 100, 132-137.	3.9	8
83	Glypicanâ€3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Science, 2009, 100, 1403-1407.	3.9	222
84	Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncology Reports, 2009, 22, 149-54.	2.6	8
85	Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Research, 2008, 18, 166-171.	1.2	17
86	HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. International Journal of Oncology, 2008, 32, 985-90.	3.3	21
87	Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochemical and Biophysical Research Communications, 2006, 343, 269-278.	2.1	16
88	Embryonic Stem Cellâ€“Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10. Cancer Research, 2006, 66, 2414-2422.	0.9	68
89	Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Science, 2006, 97, 623-632.	3.9	53
90	Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma. Clinical Cancer Research, 2006, 12, 2689-2697.	7.0	161

#	Article	IF	Citations
91	DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4+ T cells and CD8+ T cells. Cancer Science, 2005, 96, 695-705.	3.9	29
92	Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels. Clinical Cancer Research, 2005, 11, 8079-8088.	7.0	63
93	Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma. BioDrugs, 2005, 19, 71-77.	4.6	59
94	Identification of Glypican-3 as a Novel Tumor Marker for Melanoma. Clinical Cancer Research, 2004, 10, 6612-6621.	7.0	171
95	Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cellâ€“Mediated Tumor Rejection without Autoimmune Reactions in Mice. Clinical Cancer Research, 2004, 10, 8630-8640.	7.0	87
96	Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochemical and Biophysical Research Communications, 2003, 306, 16-25.	2.1	385
97	Heat shock protein 105 is overexpressed in a variety of human tumors. Oncology Reports, 2003, 10, 1777-82.	2.6	53
98	Gene Cloning of Immunogenic Antigens Overexpressed in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 2001, 281, 936-944.	2.1	82